Beneficial hematologic effects of daily oral ascorbic acid therapy in ESRD patients with anemia and abnormal iron homeostasis: A preliminary study

Renal Failure

Volumn 30, Issue 9, 2008, Pages 884-889

  Sirover, William D ^a   Siddiqui, Aqeel A ^a   Benz, Robert L ^a  

^a LANKENAU HOSPITAL   (United States)

Author keywords

Anemia; Ascorbic acid; EPO; ESRD; Ferritin; Vitamin C

Indexed keywords

ASCORBIC ACID; ERYTHROPOIETIN; FERRITIN; HEMOGLOBIN; IRON; OXALIC ACID; TRANSFERRIN;

ADULT; AGED; ANEMIA; ARTICLE; CLINICAL ARTICLE; COST CONTROL; DRUG EFFECT; FEMALE; FERRITIN BLOOD LEVEL; HEMATOCRIT; HEMODIALYSIS PATIENT; HUMAN; HYPERFERRITINEMIA; KIDNEY FAILURE; MALE; PRIORITY JOURNAL; TREATMENT DURATION;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANEMIA; ASCORBIC ACID; COHORT STUDIES; DRUG ADMINISTRATION SCHEDULE; FEMALE; FERRITINS; HUMANS; IRON METABOLISM DISORDERS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; RENAL DIALYSIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VITAMINS;

EID: 54249090236     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.1080/08860220802353884     Document Type: Article

References (25)

1. Tarng DC, Huang TP, Chen TW, and Yang WC. Erythropoietin hyporesponsiveness: From iron deficiency to iron overload. Kidney Int Suppl. 1999;69:S107-S118.
2. Tarng DC, Huang TP. A parallel, comparative study of intravenous iron versus intravenous ascorbic acid for erythropoietin-hyporesponsive anaemia in hemodialysis patients with iron overload. Nephrol Dial Transplant. 1998;13: 2867-2872.
3. Tarng DC, Wei YH, Huang TP, Kuo BI, Yang WC. Intravenous ascorbic acid as an adjuvant therapy for recombinant erythropoietin in hemodialysis patients with hyperferritinemia. Kidney Int. 1999;55:2477-2486.
4. Keven K, Kutlay S, Nergizoglu G, Erturk S. Randomized, crossover study of the effect of vitamin C on EPO response in hemodialysis patients. Am J Kidney Dis. 2003;41:1233-1239.
5. Canavese C, Bergamo D, Ciccone G, Longo F, Fop F, Thea A, Martina G, Piga A. Validation of serum ferritin values by magnetic susceptometry in predicting iron overload in dialysis patients. Kidney Int. 2004;65:1091-1098.
6. Teehan GS, Bahdouch D, Ruthazer R, Balakrishnan VS, Snydman DR, Jaber BL. Iron storage indices: Novel predictors of bacteremia in hemodialysis patients initiating intravenous iron therapy. Clin Infect Dis. 2004;38:1090-1094.
7. Canavese C, Bergamo D, Ciccone G, Burdese M, Maddalena E, Barbieri S, Thea A, Fop F. Low-dose continuous iron therapy leads to a positive iron balance and decreased serum transferrin levels in chronic hemodialysis patients. Nephrol Dial Transplant. 2004;19:1564-1570.
8. Kalantar-Zadeh K, Kleiner M, Dunne E, Ahern K, Nelson M, Koslowe R, Luft FC. Total iron-binding capacity-estimated transferrin correlates with the nutritional subjective global assessment in hemodialysis patients. Am J Kidney Dis. 1998;31:263-272.
9. Konijn AM, Carmel N, Levy R, Hershko C. Ferritin synthesis in inflammation. II. Mechanism of increased ferritin synthesis. Br J Hematol. 1981;49:361-370.
10. Nissenson AR. Hyporesponsiveness to erythropoietin: Overview, 1996. Perit Dial Int. 1996;16:417-420.
11. Tarng DC, Huang TP. Hyporesponsiveness to erythropoietin. Perit Dial Int. 1997;17:99-100.
12. Gunnell J, Yeun JY, Depner TA, Kaysen GA. Acute-phase response predicts erythropoietin resistance in hemodialysis and peritoneal dialysis patients. Am J Kidney Dis. 1999;33:63-72.
13. el-Reshaid K, Johny KV, Hakim A, Kamel H, Sebeta A, Hourani H, Kanyike FB. Erythropoietin treatment in hemodialysis patients with iron overload. Acta Hematol. 1994;91:130-135.
14. Bothwell TH, Bradlow BA, Jacobs P, Keeley K, Kramer S, Seftel H, Zail S. Iron Metabolism in Scurvy with Special Reference to Erythropoiesis. Br J Hematol. 1964;10:50-58.
15. Mydlik M, Derzsiova K, Boldizsar J, Hribikova M, Petrovicova J. Oral use of iron with vitamin C in hemodialyzed patients. J Ren Nutr. 2003;13:47-51.
16. Lin CL, Hsu PY, Yang HY, Huang CC. Low dose intravenous ascorbic acid for erythropoietin-hyporesponsive anemia in diabetic hemodialysis patients with iron overload. Ren Fail. 2003;25:445-453.
17. Gastaldello K, Vereerstraeten A, Nzame-Nze T, Vanherweghem JL, Tielemans C. Resistance to erythropoietin in iron-overloaded hemodialysis patients can be overcome by ascorbic acid administration. Nephrol Dial Transplant. 1995;10 (Suppl. 6):44-47.
18. Attallah N, Osman-Malik Y, Frinak S, Besarab A. Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia. Am J Kidney Dis. 2006;47:644-654.
19. Goldberg A. The enzymic formation of hem by the incorporation of iron into protoporphyrin: Importance of ascorbic acid, ergothioneine and glutathione. Br J Hematol. 1959;5:150-157.
20. Lipschitz DA, Bothwell TH, Seftel HC, Wapnick AA, Charlton RW. The role of ascorbic acid in the metabolism of storage iron. Br J Hematol. 1971;20:155-163.
21. Bridges KR, Hoffman KE. The effects of ascorbic acid on the intracellular metabolism of iron and ferritin. J Biol Chem. 1986;261:14273-14277.
22. Ali M, Rigolosi R, Fayemi AO, Braun EV, Frascino J, Singer R. Failure of serum ferritin levels to predict bone-marrow iron content after intravenous iron-dextran therapy. Lancet. 1982;1:652-655.
23. Zhang Y, Thamer M, Stefanik K, Kaufman J, Cotter DJ. Epoetin requirements predict mortality in hemodialysis patients. Am J Kidney Dis. 2004;44:866-876.
24. Descombes E, Hanck AB, Fellay G. Water soluble vitamins in chronic hemodialysis patients and need for supplementation. Kidney Int. 1993;43:1319-1328.
25. Deicher R, Ziai F, Habicht A, Bieglmayer C, Schillinger M, Horl WH. Vitamin C plasma level and response to erythropoietin in patients on maintenance hemodialysis. Nephrol Dial Transplant. 2004;19:2319-2324.